Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]2CC[C@]3(C)[C@@H]2[C@H](O)C[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5[C@H](C[C@@]34C)O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=LLPWNQMSUYAGQI-OOSPGMBYSA-N
InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1
| Molecular Formula | C47H80O18 |
| Molecular Weight | 933.1273 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27571993 | https://www.ncbi.nlm.nih.gov/pubmed/25503068 | https://www.ncbi.nlm.nih.gov/pubmed/25203723
Notoginsenoside R1 is a characteristic constituent of Radix notoginseng, a well known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as diabetic nephropathy, cardiovascular disease, cerebral vascular disease, and liver dysfunction. Notoginsenoside R1 has multiple pharmacologic activities, including cardioprotective, neuroprotective, anti-inflammatory, and anticancer effects. A study on the application of Notoginsenoside R1 in a rat model of diabetic nephropathy indicated that Notoginsenoside R1 ameliorated the glucose-induced impairment of podocyte adhesive capacity and subsequent podocyte depopulation, partly through the upregulation of α3β1 integrin via PI3K-Akt signaling pathway activation.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs. | 2016 |
|
| Role of Chinese herbal medicinal ingredients in secretion of cytokines by PCV2-induced endothelial cells. | 2016 |
|
| Notoginsenoside R1 stimulates osteogenic function in primary osteoblasts via estrogen receptor signaling. | 2015-10-16 |
|
| Estrogen receptor α mediates the effects of notoginsenoside R1 on endotoxin-induced inflammatory and apoptotic responses in H9c2 cardiomyocytes. | 2015-07 |
|
| Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. | 2015-02 |
|
| Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. | 2015-02 |
|
| Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457. | 2015 |
|
| Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation. | 2015 |
|
| ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. | 2014-12-15 |
|
| Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice. | 2014-10 |
|
| Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. | 2014-09-12 |
|
| Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. | 2014-09 |
|
| Dissecting active ingredients of Chinese medicine by content-weighted ingredient-target network. | 2014-07 |
|
| Suppression of NADPH oxidase- and mitochondrion-derived superoxide by Notoginsenoside R1 protects against cerebral ischemia-reperfusion injury through estrogen receptor-dependent activation of Akt/Nrf2 pathways. | 2014-07 |
|
| Notoginsenoside R1-mediated neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: a novel mechanism of Nrf2/ARE signaling activation. | 2014-04 |
|
| Protective effects of Notoginsenoside R1 on intestinal ischemia-reperfusion injury in rats. | 2014-01 |
|
| Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo. | 2014 |
|
| Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies. | 2014 |
|
| Notoginsenoside R1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of ERK. | 2014 |
|
| Notoginsenoside R1 attenuates atherosclerotic lesions in ApoE deficient mouse model. | 2014 |
|
| Notoginsenoside R1 attenuates cardiac dysfunction in endotoxemic mice: an insight into oestrogen receptor activation and PI3K/Akt signalling. | 2013-04 |
|
| Notoginsenoside R1 attenuates renal ischemia-reperfusion injury in rats. | 2010-09 |
|
| Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly. | 2009-07 |
|
| Effect of notoginsenoside R1 on hepatic microcirculation disturbance induced by gut ischemia and reperfusion. | 2008-01-07 |
|
| Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. | 2007-07-19 |
|
| Ginsenoside Re and notoginsenoside R1: Immunologic adjuvants with low haemolytic effect. | 2006-07 |
|
| Notoginsenoside R1 inhibits TNF-alpha-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. | 2006-05-01 |
|
| Notoginsenoside R1 from Panax notoginseng inhibits TNF-alpha-induced PAI-1 production in human aortic smooth muscle cells. | 2006-04 |
|
| Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery. | 1997-06 |
|
| Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. | 1997-03 |
|
| Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. | 1994-07 |
Patents
Sample Use Guides
Notoginsenoside R1 was administrated orally at doses 5, 10 and 20 mg/kg•day to rats with diabetic nephropathy. Notoginsenoside R1was administered during 16 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: High glucose decreased podocyte adhesive capacity and α3β1 integrin expression, the main podocyte anchoring dimer to the glomerular basement membrane. However, Notoginsenoside R1 ameliorated impaired podocyte adhesive capacity and partially restored α3β1 integrin protein and mRNA expression.
Treatment with 10 and 100 μg/ml of Notoginsenoside R1 for 24 hours significantly increased the adhesion of podocytes to basement membrane protein complex
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:46:06 GMT 2025
by
admin
on
Mon Mar 31 22:46:06 GMT 2025
|
| Record UNII |
Z62692362Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z62692362Z
Created by
admin on Mon Mar 31 22:46:06 GMT 2025 , Edited by admin on Mon Mar 31 22:46:06 GMT 2025
|
PRIMARY | |||
|
DTXSID101036451
Created by
admin on Mon Mar 31 22:46:06 GMT 2025 , Edited by admin on Mon Mar 31 22:46:06 GMT 2025
|
PRIMARY | |||
|
80418-24-2
Created by
admin on Mon Mar 31 22:46:06 GMT 2025 , Edited by admin on Mon Mar 31 22:46:06 GMT 2025
|
PRIMARY | |||
|
8111
Created by
admin on Mon Mar 31 22:46:06 GMT 2025 , Edited by admin on Mon Mar 31 22:46:06 GMT 2025
|
PRIMARY | |||
|
441934
Created by
admin on Mon Mar 31 22:46:06 GMT 2025 , Edited by admin on Mon Mar 31 22:46:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
